Oncorhynchus mykiss specific CpG adjuvant, application thereof and oncorhynchus mykiss infectious hematopoietic necrosis nucleic acid vaccine
By introducing a rainbow trout-specific CpG adjuvant and a gene encoding a glycoprotein into a nucleic acid vaccine for infectious hematopoietic necrosis of the rainbow trout, and combining it with the pCDNA3.1 vector, the problem of insufficient heterologous protective capacity of existing nucleic acid vaccines was solved, and a highly efficient immune protection effect was achieved.
Patent Information
- Application Number
- CN202411005298.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-25
- Publication Date
- 2024-11-08
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing nucleic acid vaccines constructed against different genotypes of IHNV strains have poor heterologous protection capabilities and are difficult to effectively resist infection by the J genotype IHNV native to China, resulting in economic losses for the rainbow trout farming industry.
A rainbow trout-specific CpG adjuvant and its application were designed. By combining the gene encoding the rainbow trout infectious hematopoietic necrosis glycoprotein and the pCDNA3.1 vector, a rainbow trout infectious hematopoietic necrosis nucleic acid vaccine was constructed. Based on the optimization of the immunization dose, the CpG adjuvant was added to optimize the immunoprotective effect.
It significantly improved the immune protection rate to 94.74%, effectively resisting high concentrations of viral invasion and enhancing the protective effect of nucleic acid vaccines.
Smart Images

Figure CN118903403A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of molecular biology and immunology, and specifically relates to a rainbow trout-specific CpG adjuvant and application thereof, and a rainbow trout infectious hematopoietic necrosis disease nucleic acid vaccine. Background Art
[0002] Infectious haematopoietic necrosis (IHN) is a common acute viral infectious disease that mainly harms salmon and trout, and can cause up to 100% mortality in salmon and trout (Dixon et al., 2016). Since its first outbreak in the United States in the 1950s, IHN has affected more than a dozen countries including China, causing huge economic losses to salmon and trout farming industries worldwide.
[0003] Infectious haematopoietic necrosis virus (IHNV) belongs to the Rhabdoviridae family and is a virus that causes IHN. Its genome is about 11kb long and is a single-stranded negative-sense RNA virus. The genome of IHNV encodes six genes, which encode viral nucleoprotein (N), phosphoprotein (P), matrix protein (M), glycoprotein (G), nonstructural protein (NV) and polymerase protein (L). Among them, glycoprotein (G) is the surface protein of the virus, which contains rich antigenic epitopes and is regarded as the protective antigen of IHNV. In the development of antiviral immunity and vaccines, researchers often use G protein as the antigen target protein (Xu et al., 2017).
[0004] According to the G protein gene sequence, IHNV worldwide is divided into five genotypes: U, M, L, E, and J. Among them, the U, M, and L genotypes are mainly prevalent in North America, the E genotype is prevalent in Europe, and the J genotype is prevalent in Asia. Although the glycoproteins of each genotype strain have high nucleotide (>94%) and amino acid (>93%) homology (Jia et al., 2014), the pathogenicity of different genotype strains varies. Among them, the J and M genotype strains are highly virulent, and the nucleic acid vaccine constructed on this basis can provide better cross-protection effects. Under the same experimental conditions, the test fish immunized with the U genotype cannot resist the infection of the J or M genotype IHNV strains on the 28th day after immunization (Huo et al., 2022; 2011). It can be seen that the nucleic acid vaccines constructed against different genotypes of IHNV strains have poor heterologous protection ability.
[0005] In order to respond to the outbreak of J genotype IHNV in China, an IHNV nucleic acid vaccine suitable for China should be constructed targeting the local epidemic strains to solve the bottleneck problem restricting the development of my country's cold-water fish industry. At present, reports on IHNV nucleic acid vaccines mainly focus on the glycoprotein of M genotype IHNV strains. There are fewer reports on nucleic acid vaccines developed for J genotype IHNV strains, and they are mainly concentrated on isolates around 2009. This study is based on the IHNV isolate GS21 isolated from Gansu fishery in 2021. On the basis of optimizing the immune dose, the cytokine adjuvant CpG (named CpG-21) was added to better enhance the immune protection effect. Summary of the invention
[0006] In order to solve the above problems in the prior art, the present invention provides a rainbow trout-specific CpG adjuvant and application thereof, and a rainbow trout infectious hematopoietic necrosis disease nucleic acid vaccine.
[0007] In order to achieve the above-mentioned object, the first aspect of the present invention provides a rainbow trout-specific CpG adjuvant, the main feature of which is that the nucleotide sequence is shown in SEQ ID NO.1.
[0008] The second aspect of the present invention provides the use of the rainbow trout-specific CpG adjuvant as an adjuvant for a nucleic acid vaccine against rainbow trout infectious hematopoietic necrosis disease.
[0009] The third aspect of the present invention provides a rainbow trout infectious hematopoietic necrosis disease nucleic acid vaccine, the main characteristics of which are that it includes a gene encoding a rainbow trout infectious hematopoietic necrosis disease glycoprotein, the rainbow trout-specific CpG adjuvant and a carrier.
[0010] Preferably, the nucleotide sequence of the gene encoding rainbow trout infectious hematopoietic necrosis disease glycoprotein is as shown in SEQ ID NO.2.
[0011] Preferably, the vector is a pCDNA3.1 vector.
[0012] The nucleic acid vaccine for infectious hematopoietic necrosis of rainbow trout provided in the third aspect of the present invention can be used to prevent infectious hematopoietic necrosis of rainbow trout. In specific applications, the injection dose of the nucleic acid vaccine is preferably 10 μg / tail.
[0013] The beneficial effects of the rainbow trout-specific CpG adjuvant and application thereof, and the rainbow trout infectious hematopoietic necrosis disease nucleic acid vaccine of the present invention are: the present invention creatively adds CpG adjuvant when applying the nucleic acid vaccine, further increasing the relative immune protection rate to 94.74%, and the optimized nucleic acid vaccine can resist high concentrations of virus invasion, significantly improving the protective effect of the vaccine. BRIEF DESCRIPTION OF THE DRAWINGS
[0014] Figure 1 This is a schematic diagram of the cumulative survival rate during the 21-day observation period after the virus infection test.
[0015] Figure 2 This is the RPS result diagram of each experimental group after the virus infection test.
[0016] Figure 3a to Figure 3c These are the gene expression levels of Mx, IFN-Ⅰ and IFN-γ in rainbow trout kidney after immunization. DETAILED DESCRIPTION
[0018] In order to make the technical means, creative features, objectives and effects achieved by the present invention easy to understand, the present invention is further described below in conjunction with specific embodiments.
[0019] The rainbow trout-specific CpG adjuvant and application thereof, and the rainbow trout infectious hematopoietic necrosis disease nucleic acid vaccine provided by the present invention use the Gansu new isolate GS21, which has a unique amino acid sequence feature among the Asian isolates in the past decade: G230 / G252 / G270 / I277.
[0020] The experimental materials involved in the following examples are:
[0021] IHNV isolate GS21 was isolated from diseased rainbow trout in Gansu, the pCDNA3.1 vector was stored in the laboratory, and the CpG sequence was synthesized by JEWELL. The viral genome extraction kit and reverse transcription kit were purchased from Quanshijin. The quantitative PCR kit MonAmpSYBR×green qPCR Mix was purchased from Mona.
[0022] Example 1: Vaccine Construction
[0023] Virus culture
[0024] The virus suspension of IHNV isolate GS21 (OR1226690-OR1226695) (deposited in the China Center for Type Culture Collection CCTCC on July 10, 2024, with strain collection number CCTCC NO: V202467) was inoculated into a monolayer of confluent CHSE-214 cells at a ratio of MOI = 0.01 with MEM medium (cell maintenance fluid) containing 2% FBS, incubated in a 15°C incubator for 1h, the virus suspension was discarded, 5ml of cell maintenance fluid was added to the cell culture bottle, and cultured in a 15°C incubator for 7-10 days. When about 80% of the cells showed cytopathic effects, the virus suspension was collected and stored in a -80°C refrigerator. The stored viral RNA genome was extracted according to the instructions of the viral genome extraction kit and reversely transcribed into cDNA.
[0025] Glycoprotein sequence amplification
[0026] The full length of the glycoprotein sequence (OR1226690) was used as the amplification object, and specific amplification primers F: ATGGACGCCATGATCACC and R: GGACCTGTTTGCCAGGT were designed. PCR amplification was performed using the viral cDNA genome as a template and the above specific amplification primers as primers.
[0027] The PCR amplification procedure was as follows: 95°C pre-denaturation for 5 min, 95°C denaturation for 10 s, 52°C annealing for 20 s, 72°C extension for 20 s, 30 cycles, and 72°C final extension for 5 min. The nucleic acid vaccine antigen sequence used was as follows (OR1226690, SEQ ID NO. 2):
[0028]
[0029] The RT-PCR products were subjected to 1% agarose gel electrophoresis and then recovered.
[0030] Connection conversion
[0031] The recovered product obtained from the previous step of "glycoprotein sequence amplification" was connected to the pCDNA3.1 vector, and the ligation product was transformed into DH5α competent cells. After picking a single colony for expansion culture, the plasmid was extracted and PCR identification was performed, and the correctly identified plasmid was sequenced to construct the nucleic acid vaccine pG.
[0032] Construction of nucleic acid vaccine pG+CpG
[0033] The obtained pG plasmid was used as a vector to synthesize and insert a CpG adjuvant sequence (F: AGAGGAACTTGGTTAGGTAC R: CTTCTGAGGCGGAAAGAACC) to construct a nucleic acid vaccine pG+CpG.
[0034] The CpG adjuvant sequence is composed of CpG (2006-1668-unnamed-1681-1651-2007) combined and connected in series three times, named CpG-21, and the specific sequence is as follows (SEQ ID NO.1).
[0035] tcgtcgttttgtcgttttgtcgttccatgacgttcctgatgcttgcataacggcgagctaccgatgtcgttgccggtgacgtccatgacgtc cctgatgcttcgtcgttgtcgttttgtcgtttcgtcgttttgtcgttttgtcgttccatgacgttcctgatgcttgcataacggcgagctac cgatgtcgttgccggtgacgtccatgacgtccctgatgcttcgtcgttgtcgttttgtcgtttcgtcgttttgtcgttttgtcgttccatga cgttcctgatgcttgcataacggcgagctaccgatgtcgttgccggtgacgtccatgacgtccctgatgcttcgtcgttgtcgttttgtcgtt
[0036] Example 2 Immune Effect
[0037] immunity
[0038] Rainbow trout weighing 5±01g were randomly divided into groups, with 20 in each group, and temporarily kept in a circulating water pool (65cm×65cm×70cm) with a water temperature maintained at (13.5±1)℃. After 7 days of domestication, they were injected with nucleic acid vaccines (the injection site was the base of the dorsal fin) and fasted for 2 days before the experiment. The specific groups were: pG-1μg group, pG-10μg group, pG+CpG-10μg group, and PBS group. The pG-1μg group and pG-10μg group were injected with nucleic acid vaccines pG with an immunization dose of 1μg / tail and 10μg / tail, respectively, and the pG+CpG-10μg group was injected with a nucleic acid vaccine pG+CpG with an immunization dose of 10μg / tail. At the same time, the blank control group was injected with 50μL / tail of phosphate solution.
[0039] The challenge infection test was carried out 28 days after immunization.
[0040] Virus infection test
[0041] Take 10 4 The fry of each group were immunized with IHNV isolate GS21 at a dose of PFU / ml intraperitoneally for 28 days, and the MOCK group was set as a blank control group (injected with 50 μL / tail phosphate solution). After the challenge test, the rainbow trout of each group were temporarily placed in the circulating water tank.
[0042] The incidence and mortality of rainbow trout in each group were recorded for 3 consecutive weeks. The vaccine protection rate evaluation test was the comprehensive result of three independent repeated studies.
[0043] The results of the challenge test 28 days after immunization are as follows Figure 1 and 2 As shown. Figure 2 As shown in the figure, by increasing the immunization dose, the relative immune protection rate (RPS) was increased from 59.65% to 82.46%; on this basis, the creative addition of CpG adjuvant further increased the RPS to 94.74%. Figure 1 As shown, during the 21-day observation period, only one fish died in the pG+CpG-10μg group. The above challenge test results can prove that the optimized nucleic acid vaccine pG+CpG provided by the present invention can resist high-concentration virus invasion.
[0044] Example 3: Expression of immune gene transcription levels
[0045] In order to detect the immunogenicity of the constructed vaccine, rainbow trout were immunized with the same immunization method as in Example 2, and rainbow trout head kidney samples were collected 7, 14, 21 and 28 days after immunization. The total RNA of the head kidney was extracted using an RNA extraction kit, and the quantitative analysis of Mx-1, IFN-Ⅰ and IFN-γ was performed using the MonAmp SYBR×green qPCR Mix quantitative PCR kit. The specific groups were: pG-1μg group, pG-10μg group, pG+CpG-10μg group, and PBS group. The pG-1μg group and the pG-10μg group were injected with nucleic acid vaccine pG with an immunization dose of 1μg / tail and 10μg / tail, respectively, and the pG+CpG-10μg group was injected with a nucleic acid vaccine pG+CpG with an immunization dose of 10μg / tail. At the same time, the blank control group was injected with PBS. The head kidney samples of each group were taken from 5 rainbow trout head kidney samples.
[0046] The blank rainbow trout samples were used as negative controls, and the Mx gene expression level in the control group was set to 1.
[0047] The results of the expression levels of Mx, IFN-Ⅰ and IFN-γ genes in the kidney of rainbow trout after immunization are as follows Figure 3a to Figure 3c Specifically, Figure 3a As shown, on the 7th day after immunization, the expression level of Mx gene in the head kidney of rainbow trout in the pG+CpG group was the highest; Figure 3b and Figure 3c As shown, on the 14th day after immunization, the expression levels of IFN-Ⅰ and IFN-γ genes in the head kidney of rainbow trout in the pG+CpG group were the highest, and it can be seen that the pG+CpG group had a certain enhancement in immune gene expression compared with the pG-1μg group.
[0048] Therefore, this result can prove that the vaccines constructed by the present invention have corresponding immunogenicity, and the expression level of the optimized immune gene is enhanced, which can stimulate rainbow trout to produce nonspecific immune response.
[0049] In this specification, the present invention has been described with reference to specific embodiments thereof. However, it is apparent that various modifications and variations may be made without departing from the spirit and scope of the present invention. Therefore, the specification and drawings should be regarded as illustrative rather than restrictive.
Claims
1. A rainbow trout-specific CpG adjuvant, characterized in that: The nucleotide sequence is shown in SEQ ID NO.
1.
2. Use of the rainbow trout-specific CpG adjuvant according to claim 1 as an adjuvant for a nucleic acid vaccine against rainbow trout infectious hematopoietic necrosis disease.
3. A nucleic acid vaccine for infectious hematopoietic necrosis of rainbow trout, characterized in that: The invention comprises a gene encoding a glycoprotein of rainbow trout infectious hematopoietic necrosis disease, the rainbow trout specific CpG adjuvant as claimed in claim 1 and a carrier.
4. The nucleic acid vaccine for infectious hematopoietic necrosis of rainbow trout according to claim 3, characterized in that: The nucleotide sequence of the gene encoding rainbow trout infectious hematopoietic necrosis disease glycoprotein is shown in SEQ ID NO.
2.
5. The nucleic acid vaccine for infectious hematopoietic necrosis of rainbow trout according to claim 3, characterized in that: The vector is pCDNA3.1 vector.
Citation Information
Patent Citations
Infectious hematopoietic necrosis (IHN) nucleic acid vaccines for Chinese rainbow trout and application thereof
CN105816871A
Sequence, plasmid, and engineering bacteria for use in disease control of aquatic animal and application thereof
CN1970772A
IHNV G protein for immune stimulation
US20050163795A1
Cited By
Rainbow trout nucleic acid vaccine adjuvant and application thereof
CN119909166A
Linear covalent closed DNA vaccine as well as preparation method and application thereof
CN120000774A
